Department of Infectious, Parasitic and Immune-mediated Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Expert Opin Biol Ther. 2011 Jun;11(6):739-50. doi: 10.1517/14712598.2011.571670. Epub 2011 Mar 25.
The development of new strategies for the induction of potent and broad immune responses is of high priority in the vaccine field. In this setting, integrase-defective lentiviral vectors (IDLV) represent a new and promising delivery system for immunization purposes.
In this review we describe the development and application of IDLV for vaccination. IDLV are turning out to be a new class of vectors endowed with peculiar characteristics, setting them apart from the parental integration-competent lentiviral vectors. Recent data suggest that IDLV are able to induce strong antigen-specific immune responses in terms of quantity, persistence and quality of CD8(+) T cell response following a single immunization in mice.
IDLV are a recent acquisition in the field of genetic immunization, thus allowing for the opportunity of further upgrading, including increasing antigen expression and potency of immune response. Based on recent reports showing the potential of IDLV for immunization in mouse models, further development and validation of IDLV, including comparison with other vaccine protocols and use in non-human primate models, are warranted.
在疫苗领域，开发能够诱导强效且广泛免疫应答的新策略至关重要。在这种情况下，整合酶缺陷型慢病毒载体（IDLV）代表了一种用于免疫接种的新型且有前途的传递系统。
在这篇综述中，我们描述了 IDLV 的开发和应用，用于疫苗接种。IDLV 正在成为一类新型载体，具有独特的特性，使其有别于亲本整合型慢病毒载体。最近的数据表明，IDLV 能够在单次免疫后诱导强烈的抗原特异性免疫应答，在 CD8(+)T 细胞应答的数量、持久性和质量方面均有体现。
IDLV 是基因免疫领域的一项新成果，因此有机会进一步升级，包括增加抗原表达和免疫应答的效力。基于最近的报告显示 IDLV 在小鼠模型中免疫接种的潜力，需要进一步开发和验证 IDLV，包括与其他疫苗方案进行比较，并在非人类灵长类动物模型中使用。
